GLP-1 Drugs and Blood Pressure: How Much They Lower It, and Why
Blood-pressure reduction is one of the most reproducible secondary effects of GLP-1 and dual GIP/GLP-1 receptor agonists. It shows up across the obesity and diabetes trial programmes, and it is part of the mechanism by which these drugs lower cardiovascular risk.
This article awaits medical-reviewer signoff.
What the trials show
STEP 1 — semaglutide 2.4 mg (Wegovy)
Published: NEJM, 2021 Population: 1,961 adults with overweight or obesity, without type 2 diabetes Drug: Semaglutide 2.4 mg weekly Duration: 68 weeks
Systolic blood pressure fell by approximately 6 mmHg from baseline on semaglutide, compared with a small change on placebo — a placebo-adjusted reduction of roughly 5 mmHg. Diastolic pressure fell modestly as well.
SURMOUNT-1 ambulatory blood-pressure substudy — tirzepatide (Zepbound)
Published: Hypertension (American Heart Association), 2024 Population: A subset of SURMOUNT-1 participants (BMI ≥27) wearing a 24-hour ambulatory blood-pressure monitor Drug: Tirzepatide 5, 10, or 15 mg weekly
Twenty-four-hour systolic blood pressure fell by roughly 7–8 mmHg on average, with larger reductions at higher doses. Because this used 24-hour ambulatory monitoring rather than a single clinic reading, it is a more reliable estimate of the true effect.
SELECT — semaglutide 2.4 mg, cardiovascular population
Published: NEJM, 2023
In the large cardiovascular-outcomes trial of semaglutide in adults with established cardiovascular disease and obesity, blood pressure was again lower on treatment. The blood-pressure effect is one of several mechanisms thought to contribute to the 20% reduction in major adverse cardiovascular events seen in that trial.
Why a few mmHg matters
A 5–6 mmHg reduction sounds small on an individual cuff reading. At a population level, however, sustained systolic reductions of this size are associated with meaningfully fewer strokes and cardiac events. For someone with borderline or treated hypertension and obesity, the blood-pressure effect of a GLP-1 is a genuine clinical bonus on top of weight loss and glucose control.
What drives the effect
Weight loss is the main driver. The size of the blood-pressure reduction tracks with the amount of weight lost, and weight loss reduces blood pressure through several well-understood pathways.
Direct effects probably contribute. GLP-1 receptors are expressed in vascular and kidney tissue. Proposed mechanisms include improved endothelial function and effects on sodium handling (natriuresis). The early timing of the blood-pressure drop is consistent with some weight-independent contribution.
Clinical implications
- No GLP-1 drug is FDA-approved as a blood-pressure medication. The blood-pressure benefit is a secondary effect, not an indication.
- It does not replace dedicated antihypertensives. People with hypertension should continue their prescribed blood-pressure regimen unless their prescriber decides to adjust it.
- Monitor, especially early. If your blood pressure was already treated, it can fall further on a GLP-1. Some people need their antihypertensive doses reviewed — a decision for the prescriber managing your blood pressure, with monitoring.
Part of: GLP-1 Benefits Beyond Weight Loss. Related reading: GLP-1 drugs and heart health and how GLP-1 drugs work.
Editorial note: This article awaits medical-reviewer signoff. Blood-pressure management is a clinical domain; do not change or stop any blood-pressure medication without the prescriber who manages it.
Frequently asked questions
Does semaglutide (Ozempic/Wegovy) lower blood pressure?
Yes. In the STEP 1 obesity trial (NEJM 2021), semaglutide 2.4 mg lowered systolic blood pressure by about 6 mmHg from baseline, roughly 5 mmHg more than placebo. The effect is consistent across the semaglutide trial programme, though no semaglutide product is FDA-approved specifically to treat high blood pressure. This page awaits medical reviewer signoff.
How much does tirzepatide lower blood pressure?
In the SURMOUNT-1 ambulatory blood-pressure monitoring substudy (Hypertension, 2024), tirzepatide lowered 24-hour systolic blood pressure by approximately 7–8 mmHg on average, with larger reductions at higher doses. Ambulatory monitoring (a 24-hour cuff) is considered more reliable than a single clinic reading.
Can I stop my blood-pressure medication if I take a GLP-1?
Not on your own. Some people on a GLP-1 do see their blood pressure fall enough that their prescriber reduces or adjusts antihypertensive medication, but that is a clinical decision made with monitoring. Stopping a blood-pressure drug abruptly can be dangerous. Discuss any changes with the prescriber managing your blood pressure.
Is the blood-pressure drop just from losing weight?
Largely, but not entirely. The magnitude of blood-pressure reduction tracks with the amount of weight lost, which points to weight loss as the main driver. However, pressure starts falling early and GLP-1 receptors are present in blood-vessel and kidney tissue, so direct vascular and sodium-handling effects probably contribute as well.